NSISBC.XD DXE
Novonesis (Novozymes) B
1W: -1.6%
1M: -7.6%
3M: -2.5%
YTD: +7.9%
1Y: -0.6%
kr 421.35 ($63.20)
+3.95 (+0.95%)
Weekly Expected Move ±3.1%
kr 391
kr 404
kr 417
kr 431
kr 444
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Capkr 116.0B ($17.4B)
52W Range336.8-465
Volume244,844
Avg Volume274,099
Beta0.93
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOEster Baiget
Employees10,582
SectorBasic Materials
IndustryChemicals - Specialty
IPO Date2000-11-13
Websitenovonesis.com
Biologiens Vej 2
Kongens Lyngby 2800
DK
Kongens Lyngby 2800
DK
+45 44 46 00 00
About Novonesis (Novozymes) B
Established in January 2024 through the amalgamation of Novozymes A/S and Chr. Hansen, Novonesis now stands as a prominent global leader in biosolutions. The firm's activities encompass the worldwide development and commercialization of industrial enzymes, diverse microorganisms, and vital biopharmaceutical ingredients. Distinctively, its Class B shares are listed independently and actively traded on various European exchanges.
Latest News
No recent news
Recent Insider Trades
No insider trades found